Followers | 37 |
Posts | 2036 |
Boards Moderated | 0 |
Alias Born | 09/29/2007 |
Thursday, October 22, 2009 1:24:20 AM
I've looked over 10q and could not find royalty agreement with Elan over Bapineuzumab. Even a mid-single digit percentage would be substantial for Intellect. You know better than I do having invested in TTNP at going out of business prices. Alzheimer's market is a big market and will get much bigger going forward.
Company is cash strapped and that may hamper future development and progress, but the threat of bankruptcy is nil as far as I am concerned. However, failure of Bapieuzumab and shaky financial may cause the stock to take a big hit, but no bk. Company's understanding of Alzheimer's disease, patent portfolio and drug candidates will provide strong support for the stock price.
I took lots profits off the table on AVAX. Just ran up too much too fast in less than 2 month period. Had 730k free AVAX shares. :)
Waiting for a pullback to reenter here.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM